Clinical Trial Update: Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and activity of BPX-601, a PSCA-targeted CAR-T cell therapy, in selected advanced solid tumors including metastatic castrati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• BPX-601 (PSCA-targeted chimeric antigen receptor T cell therapy)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Status: TERMINATED